Evolution has given rise to an enormous range of organisms that are remarkable for their adaptation to particular environmental niches. However, humans are different; they are not only shaped by environmental pressures, but also have an increasingly powerful effect in changing the environment in which they live. As the atmosphere becomes more contaminated with industrial pollutants (/) , the ozone layer thins (2) , and the food we eat contains various natural products and additives with mutagenic potential (3, 4) , the changes in the biosphere become especially relevant to oncologists. Mutagens can be carcinogens and, because the average individual in the population lives longer than in the past, exposure increases. While it is true that genetic variability is the substrate for evolutionary selective pressures, it is known that, from bacteria to humans, extensive homeostatic safeguards have developed at the cellular level to prevent excessive random mutation (5) . Virtually all normal somatic cells contain machinery for the repair of diverse genetic lesions; additionally, conserved cell cycle checkpoints have evolved to ensure the fidelity of DNA synthesis before cell division. In the course of metazoan evolution, other safeguards (e.g., apoptotic pathways) were developed to prevent aberrant single cells from destroying the precise developmental patterns of tissues and organ systems required for survival of the organism as a whole (6) .
The importance of genomic stability to the integrity of the organism has become clear in recent years with the understanding that cancer is a genetic disease related, in large part, to genetic instability and the absence of the mechanisms that protect against it. The regulated genetic adaptability that gives rise to individual organisms that are able to survive under diverse selective pressures over evolutionary time is subverted by renegade cells with logarithmic increases in mutation frequencies and no functional suicide switch to prevent uncontrolled outgrowth of heterogeneous, malignant progeny. Cancer thus becomes an exceedingly unpredictable adversary; for every strategy of attack we can imagine, there appear to be several genetic mechanisms to counter us. (Can a parallel be made with human immunodeficiency virus?) Mechanisms of tumor drug resistance are illustrative. They include alterations in drug transport, defective metabolism to active moieties, increased metabolic inactivation, gene amplification with an increase in the drug target, genetic alteration of the target, and others (7) .
In light of these considerations, what role will immunotherapy have in the future treatment of cancer and how effective can it be? In selected murine models, cell-mediated immunity can be induced against tumor cells, often with protection against tumor challenge subsequent to vaccination (8) . However, only rarely has this immune response resulted in effective treatment of an established, vascularized tumor. It appears that immunogenic tumor models (e.g., tumors induced by carcinogens) are more likely to successfully elicit immunity than more poorly immunogenic spontaneously arising tumors. Effector mechanisms vary in different models, but in most cases CD8 + cytotoxic T cells have a critical role. Human tumors are poorly immunogenic, a fact supported by the very existence of macroscopic tumors (an implied failure of immune surveillance) and the demonstrated difficulty in inducing antitumor responses in clinical immunotherapy trials. However, several findings during the last 3 years in patients with melanoma have given rise to optimism that at least some tumor types may be susceptible to immune attack. In at least some patients, the T-cell repertoire includes class I major histocompatibility complex (MHC)-restricted cytotoxic T lymphocytes (CTL) that recognize tumor-associated antigens on autologous tumor cells (9) . The tumor-associated antigens are often intracellular proteins. Genes encoding some of these antigens have been cloned, and relevant class I binding peptides have been defined (10) . These results permit the design of sophisticated vaccine strategies and allow detailed monitoring of the induction of specific T-cell responses. Clinical studies that are beginning now and that will continue into the next decade must determine whether tumor-specific CTL can be induced and expanded and whether these effector cells have efficacy in vivo. A critical test will be to determine the clinical outcome of patients treated with immunotherapeutic strategies that result in sufficiently large numbers of clonal or oligoclonal CTL with defined specificities for processed tumor antigens presented by self class I MHC molecules.
Any therapeutic strategy must be viewed in the context of the genetic instability of cancer cells and the mutator phenotype in particular. A current leading paradigm of oncogenesis is that genetic changes result in loss of normal cell cycle control mechanisms and abrogation of homeostatic programs to eliminate such abnormal cells (i.e., apoptosis). Metastatic and angiogenic functions contribute to the full cancer phenotype. Genetic instability of tumor cells is apparent at the chromosomal level by karyotype analysis and also using more sophisticated techniques that demonstrate microheterogeneity at the DNA level. At least two mechanisms are now well defined. Tumors in which cells are deficient or defective in expression of wild-type p53 protein (about 50% of all human tumors) are also deficient in G1 arrest-repair-apoptosis mechanisms and have a resulting increased frequency of selectable chromosomal abnormalities and aneuploidy (11). Loss of DNA mismatch repair functions (12) can lead to very high mutation rates in a number of tumor histologies, including common tumors such as cancers of the breast, lung, colon, bladder, ovary, and pancreas and less common tumors such as soft tissue sarcomas. Cancer patients with 1 g to 1 kg of tumor have 10 9 -10 12 tumor cells; thus, genetic instability will result in rather common clonal heterogeneity that can be expected to increase rapidly as the tumor grows and spreads in the absence of normal checkpoint controls and repair. Therapy of nearly any sort can be expected to select for the outgrowth of resistant clones that occur spontaneously in the tumor population.
Assuming that vaccination attempts are successful at expanding a population of host T cells capable of recognizing a tumorassociated antigen and that they are capable of trafficking to sites of tumors (neither of which is a given), how might a clonally heterogeneous mixture of tumor cells escape killing? In this issue of the Journal, Sanda et al. The LNCaP cell line expressed adequate levels of class I MHC and TAP-2 mRNAs but appeared to produce very low levels of pVmicroglobulin message. Interferon gamma had no influence on the levels of any of the three messages and did not augment surface expression of class I MHC molecules. Despite this defect, LNCaP was lysed in the vaccinia-K d assay. These data may be reconciled as follows. Targets infected by the recombinant vaccinia virus will express high levels of viral antigens and recombinant K d molecules. Given the increased affinity of human pVmicroglobulin for murine class I molecules, and the ability of CTL to recognize targets expressing fewer than 200 antigen-MHC complexes, the low levels of pVmicroglobulin would suffice for this assay. However, (^-microglobulin would be limiting for surface expression of endogenous human class I molecules. Although Sanda et al. did not perform this experiment, it seems likely that transfection of LNCaP with a pVmicroglobulin expression vector would have restored class I MHC expression to normal levels. Thus, two of five prostate cancer cell lines were poor antigen-presenting cells because of decreased class I MHC molecule expression on the cell surface. The mechanism of the defect was distinct in the two cell lines.
Previous data (14) demonstrated that three small-cell lung cancer cell lines (from a total of 27 assorted tumor lines examined) had antigen processing defects that were caused by decreased expression of TAP-2 and class I MHC molecules, and all three cell lines augmented class I expression after treatment with interferon gamma in vitro. But do these in vitro data with cell lines accurately reflect the in vivo status of human tumors? Staining of human tumor specimens with reagents specific for pan-class I MHC expression, or with locus-or allele-specific reagents, demonstrates that heterogeneity of class I expression exists in vivo at each level (15) . In breast, colon, laryngeal, and cervical carcinomas, 10%-20% of cases demonstrate heterogeneous loss of reactivity with antibody w6/32 that recognizes a combinatorial determinant formed by class I MHC molecules and pVmicroglobulin. Immunohistochemical analysis of TAP-1 protein expression in cervical carcinoma specimens showed absence of expression in 37 of 76 cases (16) . In 28 of these, congruent loss of HLA-A/B expression was noted at the single cell level. An additional mechanism was found to account for the absence of surface class I expression observed in 15 of 200 colon cancer specimens tested. A complete lack of immunostaining for pVmicroglobulin and a loss of in situ hybridization for pVmicroglobulin mRNA was noted (17) , although cytoplasmic class I heavy chain was expressed. Thus, the absence of class I MHC molecule expression found in vivo is not an artifact of long-term tissue culture and occurs by at least two distinct mechanisms.
The selective loss of class I MHC allospecificities has been observed in a number of tumor histologies (75). For example, in melanoma, HLA-A2 staining was absent in 21% of primary lesions and 44% of metastases (18) . Allele-specific losses must occur by mechanisms distinct from those described above. These mechanisms remain to be elucidated but could be influenced by the mutator phenotype. Overall, heterogeneity of class I MHC expression within tumor populations can be expected to be extensive and constitutes a significant obstacle to antigen-specific T-cell therapy. It remains unclear whether administration of interferon gamma in vivo may influence class I MHC expression in a proportion of patients. Interestingly, allele-specific loss could be regarded as evidence that the immune system does attempt to eradicate cancer in vivo, since immunologic selection against tumor cells bearing MHC alleles that present important tumor antigens would be expected to give rise to variants lacking these molecules.
Other mechanisms of tumor escape from immune attack are also likely to operate in vivo. Loss of expression of specific Tcell antigen has been described in murine models and in human clinical studies (79). Tumor antigens that are not required for proliferation, angiogenesis, or other functions essential for tumor survival are likely to be selected against by an effective immune response. Selection would also be expected to favor tumor cells that express low levels of adhesion molecules that stabilize T-cell-target conjugates. Although T-cell killing occurs by p53-independent apoptotic pathways, it is possible that cells resistant to lytic mechanisms mediated by performs and granzymes (especially aspase) will be found. Tumor-host interactions may also lead to a general downregulation of T-cell functions in patients with large tumor burdens (20) . Tumor cell products appear to influence fundamental aspects of T-cell sig-nal transduction and gene expression. In addition, the tumor may tolerize (i.e., render unresponsive) the peripheral T cells capable of recognizing it because of the lack of expression of costimulatory molecules by the tumor (27). Furthermore, the increased interstitial pressure that is characteristic of tumor masses may form a biophysical barrier to tumor penetration by host effector cells (22) .
Continued study of tumor escape mechanisms is critical for the formulation of effective immunotherapy approaches. The apparent multiplicity of mechanisms for avoiding class I MHCmediated killing has led Sanda et al. (13) to speculate that strategies to induce class II MHC-specific immune responses may be more efficacious. This effect has been shown to be true in some murine systems (23) , and recently a shared class II MHC-restricted human melanoma antigen was identified (24) . However, it must be noted that the regulation of class II MHC gene expression is more complicated than class I gene expression in that class II genes are normally more restricted in their tissue-specific expression. Furthermore, the cell biology of antigen presentation by class II MHC molecules is complex and, in all likelihood, subject to modulation in various ways within heterogeneous and genetically unstable tumor cell populations undergoing immunologic selection. Most human tumors do not express class II MHC antigens, and where it has been studied, expression is heterogeneous within tumors in which they are expressed (75).
Nevertheless, for cellular immunotherapy to successfully treat the panoply of tumor clones within an individual patient, activation of multiple effector pathways may be required. With the identification of tumor antigens and a detailed understanding of the mechanisms of antigen processing and presentation, it may be possible to monitor the evolving tumor cell and effector cell populations and manipulate therapy accordingly. Paradoxically, the feature of the tumor that is contributing to our difficulties may provide a crucial vulnerability; for while the mutator phenotype will increase the frequency of tumor cells resistant to ongoing selective pressures, it is also expected to generate mutant gene products that encode novel, tumor-specific epitopes. The large repertoire of clonotypic T-cell receptors that formed the basis for early enthusiasm for tumor-specific therapies may be even more relevant in the setting of a rapidly evolving tumor cell population. The challenge is to harness the various aspects of the immunologic weaponry and regulate its activity even as the patient's tumor evolves under selective pressures. As we acquire skills in manipulating the immune system, it is also expected that we may learn more about the mechanisms used by the tumor cell to restructure its genome (e.g., selective gene methylation and demethylation, chromosome rearrangements, and moveable genetic elements). This basic science knowledge may permit intervention to prevent the dynamic cancer cell genome from adapting to the selective pressures exerted by our therapies.
